argenx SE Key Executives
This section highlights argenx SE's key executives, including their titles and compensation details.
Find Contacts at argenx SE
(Showing 0 of )
argenx SE Earnings
This section highlights argenx SE's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|---|---|---|---|---|
| Read Transcript | Q4 | 2024 | 2025-02-27 | N/A | N/A |
| Read Transcript | Q3 | 2024 | 2024-10-31 | $0.10 | $1.39 |
| Read Transcript | Q2 | 2024 | 2024-07-25 | N/A | N/A |
| Read Transcript | Q1 | 2024 | 2024-05-09 | $-0.71 | $-1.04 |
argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.
$607.95
Stock Price
$36.94B
Market Cap
200.00K
Employees
Amsterdam, None
Location
Financial Statements
Access annual & quarterly financial statements for argenx SE, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Revenue | $2.19B | $1.23B | $410.75M | $497.28M | $41.24M |
| Cost of Revenue | $227.29M | $117.83M | $29.43M | $- | $- |
| Gross Profit | $1.96B | $1.11B | $381.32M | $497.28M | $41.24M |
| Gross Profit Ratio | 89.62% | 90.39% | 92.83% | 100.00% | 100.00% |
| Research and Development Expenses | $949.30M | $859.49M | $663.37M | $580.52M | $370.88M |
| General and Administrative Expenses | $745.20M | $507.39M | $353.97M | $245.55M | $170.55M |
| Selling and Marketing Expenses | $306.99M | $202.15M | $115.95M | $59.97M | $- |
| Selling General and Administrative Expenses | $1.02B | $709.54M | $469.92M | $305.52M | $170.55M |
| Other Expenses | $16.58M | $-35.50M | $-31.63M | $-40.02M | $-22.58M |
| Operating Expenses | $1.98B | $1.53B | $1.10B | $846.02M | $518.86M |
| Cost and Expenses | $2.19B | $1.65B | $1.13B | $846.02M | $518.86M |
| Interest Income | $138.74M | $92.96M | $24.74M | $3.49M | $- |
| Interest Expense | $2.46M | $904.00K | $2.19M | $1.10M | $- |
| Depreciation and Amortization | $17.53M | $111.31M | $104.34M | $5.87M | $3.92M |
| EBITDA | $3.39M | $-192.28M | $-622.78M | $-392.78M | $-601.03M |
| EBITDA Ratio | 0.16% | -15.68% | -151.62% | -78.99% | -1457.30% |
| Operating Income | $-21.65M | $-425.05M | $-720.34M | $-348.75M | $-477.62M |
| Operating Income Ratio | -0.99% | -34.66% | -175.37% | -70.13% | -1158.06% |
| Total Other Income Expenses Net | $106.83M | $120.55M | $-8.97M | $-51.00M | $-127.73M |
| Income Before Tax | $85.18M | $-304.50M | $-729.31M | $-399.74M | $-605.35M |
| Income Before Tax Ratio | 3.89% | -24.83% | -177.56% | -80.39% | -1467.77% |
| Income Tax Expense | $-746.54M | $-9.44M | $-19.72M | $8.52M | $3.10M |
| Net Income | $804.13M | $-295.05M | $-709.59M | $-408.26M | $-608.46M |
| Net Income Ratio | 36.71% | -24.06% | -172.76% | -82.10% | -1475.29% |
| EPS | $13.92 | $-5.16 | $0.00 | $0.00 | $-13.40 |
| EPS Diluted | $12.78 | $-5.16 | $0.00 | $0.00 | $-13.40 |
| Weighted Average Shares Outstanding | 59.86M | 57.17M | - | - | 45.41M |
| Weighted Average Shares Outstanding Diluted | 65.18M | 57.17M | - | - | 45.41M |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | December 31, 2024 | June 30, 2024 | December 31, 2023 | June 30, 2023 | December 31, 2022 | June 30, 2022 | December 31, 2021 | June 30, 2021 | December 31, 2020 | June 30, 2020 | December 31, 2019 | June 30, 2019 | December 31, 2018 | June 30, 2018 | December 31, 2017 | June 30, 2017 | December 31, 2016 | June 30, 2016 | December 31, 2015 | June 30, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.30B | $841.96M | $686.31M | $468.20M | $302.91M | $111.35M | $26.04M | $420.44M | $22.64M | $30.53M | $31.29M | $51.30M | $8.73M | $20.50M | $17.37M | $23.88M | $10.18M | $6.97M | $5.61M | $4.35M |
| Cost of Revenue | $641.82M | $509.52M | $519.57M | $369.97M | $380.59M | $272.29M | $269.39M | $230.96M | $148.69M | $168.41M | $119.36M | $78.30M | $49.24M | $34.37M | $26.15M | $25.59M | $20.29M | $11.26M | $11.35M | $9.28M |
| Gross Profit | $661.43M | $332.44M | $166.74M | $98.23M | $-77.68M | $-160.93M | $-243.35M | $189.49M | $-126.04M | $-137.89M | $-88.08M | $-27.00M | $-40.51M | $-13.87M | $-8.78M | $-1.71M | $-10.12M | $-4.29M | $-5.74M | $-4.94M |
| Gross Profit Ratio | 50.75% | 39.48% | 24.29% | 20.98% | -25.65% | -144.52% | -934.56% | 45.07% | -556.71% | -451.72% | -281.53% | -52.64% | -463.82% | -67.68% | -50.52% | -7.15% | -99.37% | -61.52% | -102.44% | -113.52% |
| Research and Development Expenses | $514.67M | $414.01M | $451.20M | $331.15M | $359.06M | $266.20M | $269.39M | $230.96M | $148.69M | $168.41M | $119.36M | $78.30M | $49.24M | $34.37M | $26.15M | $25.59M | $20.29M | $11.26M | $11.35M | $9.28M |
| General and Administrative Expenses | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $14.13M | $- | $- | $- | $3.06M | $3.06M | $2.61M | $2.31M |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $1.83M | $- | $- | $- | $885.00K | $- | $- | $- |
| Selling General and Administrative Expenses | $544.08M | $459.00M | $363.00M | $285.14M | $227.37M | $218.26M | $156.43M | $109.28M | $84.90M | $60.45M | $37.11M | $27.46M | $15.96M | $11.51M | $7.40M | $5.04M | $3.95M | $3.06M | $2.61M | $2.31M |
| Other Expenses | $-510.49M | $-410.92M | $-448.91M | $-329.43M | $-362.41M | $-266.20M | $-279.19M | $-230.96M | $-150.34M | $-169.25M | $-120.46M | $-78.30M | $-49.24M | $-34.37M | $-26.15M | $-25.59M | $-20.29M | $-11.26M | $-11.35M | $-9.28M |
| Operating Expenses | $562.71M | $462.09M | $365.30M | $286.86M | $224.03M | $218.26M | $146.63M | $109.28M | $83.25M | $59.62M | $36.01M | $27.46M | $15.96M | $11.51M | $7.40M | $5.04M | $3.95M | $3.06M | $2.61M | $2.31M |
| Cost and Expenses | $1.19B | $971.61M | $884.87M | $656.83M | $604.62M | $490.55M | $416.02M | $340.24M | $231.94M | $228.03M | $155.37M | $105.77M | $65.19M | $45.88M | $33.55M | $30.64M | $24.24M | $14.33M | $13.96M | $11.60M |
| Interest Income | $20.33M | $72.01M | $65.05M | $34.27M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Interest Expense | $704.00K | $365.25K | $14.65M | $696.09K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Depreciation and Amortization | $8.60M | $8.05M | $91.59M | $4.24M | $91.20M | $2.92M | $-817.98K | $2.50M | $-554.19K | $1.46M | $-335.00K | $915.00K | $259.00K | $215.00K | $215.00K | $210.00K | $178.00K | $145.00K | $106.00K | $85.00K |
| EBITDA | $125.94M | $-118.50M | $-104.68M | $-184.43M | $-213.86M | $-376.27M | $-400.60M | $82.71M | $-211.50M | $-196.87M | $-125.52M | $-53.55M | $-56.20M | $-25.17M | $-15.96M | $-6.54M | $-13.88M | $-7.21M | $-8.25M | $-7.17M |
| EBITDA Ratio | 9.66% | -14.07% | -15.25% | -39.39% | -70.60% | -337.90% | -1538.46% | 19.67% | -934.16% | -644.95% | -401.21% | -104.39% | -643.57% | -122.80% | -91.90% | -27.39% | -136.41% | -103.37% | -147.12% | -164.79% |
| Operating Income | $103.04M | $-129.65M | $-198.56M | $-188.63M | $-301.72M | $-379.19M | $-389.98M | $80.21M | $-209.30M | $-197.51M | $-124.09M | $-54.47M | $-56.46M | $-25.39M | $-16.18M | $-6.75M | $-14.06M | $-7.35M | $-8.36M | $-7.25M |
| Operating Income Ratio | 7.91% | -15.40% | -28.93% | -40.29% | -99.61% | -340.53% | -1497.69% | 19.08% | -924.42% | -647.02% | -396.63% | -106.18% | -646.54% | -123.85% | -93.13% | -28.27% | -138.16% | -105.45% | -149.01% | -166.74% |
| Total Other Income Expenses Net | $65.44M | $46.24M | $67.71M | $41.97M | $38.11M | $-47.52M | $-28.01M | $-16.12M | $-102.80M | $-1.92M | $10.64M | $9.70M | $10.72M | $5.28M | $-3.70M | $-845.00K | $45.00K | $-3.00K | $63.00K | $230.00K |
| Income Before Tax | $168.48M | $-83.41M | $-130.85M | $-146.66M | $-263.61M | $-426.71M | $-417.99M | $64.08M | $-312.09M | $-199.43M | $-113.44M | $-44.77M | $-45.74M | $-20.11M | $-19.88M | $-7.60M | $-14.02M | $-7.36M | $-8.29M | $-7.02M |
| Income Before Tax Ratio | 12.93% | -9.91% | -19.07% | -31.32% | -87.03% | -383.20% | -1605.24% | 15.24% | -1378.45% | -653.31% | -362.61% | -87.27% | -523.76% | -98.09% | -114.44% | -31.81% | -137.71% | -105.49% | -147.89% | -161.45% |
| Income Tax Expense | $-689.69M | $-52.57M | $24.78M | $-34.06M | $8.04M | $10.61M | $3.79M | $10.82M | $500.98K | $2.22M | $4.40M | $350.00K | $825.00K | $31.00K | $- | $597.00K | $- | $- | $- | $- |
| Net Income | $835.54M | $-30.37M | $-155.63M | $-112.94M | $-255.57M | $-416.10M | $-414.20M | $53.26M | $-312.59M | $-201.64M | $-117.84M | $-45.12M | $-46.56M | $-20.08M | $-19.88M | $-8.20M | $-14.02M | $-7.36M | $-8.29M | $-7.02M |
| Net Income Ratio | 64.11% | -3.61% | -22.68% | -24.12% | -84.37% | -373.67% | -1590.69% | 12.67% | -1380.67% | -660.57% | -376.68% | -87.96% | -533.21% | -97.94% | -114.44% | -34.31% | -137.71% | -105.49% | -147.89% | -161.45% |
| EPS | $11.78 | $-0.51 | $-2.65 | $-2.03 | $-4.62 | $-7.78 | $-8.04 | $0.99 | $-6.60 | $-4.64 | $-2.99 | $-1.19 | $-1.35 | $-0.62 | $-0.72 | $-0.38 | $-0.69 | $-0.42 | $-0.53 | $-0.45 |
| EPS Diluted | $11.78 | $-0.51 | $-2.65 | $-2.03 | $-4.62 | $-7.78 | $-8.04 | $0.99 | $-6.60 | $-4.64 | $-2.99 | $-1.19 | $-1.35 | $-0.62 | $-0.72 | $-0.38 | $-0.69 | $-0.42 | $-0.53 | $-0.45 |
| Weighted Average Shares Outstanding | 70.95M | 59.40M | 58.65M | 55.69M | 55.31M | 53.45M | 51.51M | 53.99M | 47.33M | 43.48M | 39.47M | 37.76M | 34.46M | 32.38M | 27.46M | 21.76M | 20.28M | 17.36M | 15.76M | 15.71M |
| Weighted Average Shares Outstanding Diluted | 70.96M | 59.40M | 58.65M | 55.69M | 55.31M | 53.45M | 51.51M | 53.99M | 47.34M | 43.48M | 39.47M | 37.76M | 34.46M | 32.38M | 27.46M | 21.76M | 20.28M | 17.36M | 15.76M | 15.71M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $1.45B | $2.05B | $800.74M | $1.33B | $1.22B |
| Short Term Investments | $1.81B | $1.13B | $1.39B | $1.00B | $779.65M |
| Cash and Short Term Investments | $3.26B | $3.18B | $2.19B | $2.34B | $2.00B |
| Net Receivables | $873.09M | $499.27M | $277.27M | $38.22M | $6.08M |
| Inventory | $393.10M | $310.55M | $228.35M | $109.08M | $25.20M |
| Other Current Assets | $185.89M | $134.07M | $76.02M | $58.95M | $29.27M |
| Total Current Assets | $4.71B | $4.12B | $2.77B | $2.54B | $2.06B |
| Property Plant Equipment Net | $42.01M | $22.68M | $16.23M | $15.84M | $11.58M |
| Goodwill | $6.30M | $- | $- | $- | $- |
| Intangible Assets | $181.44M | $125.23M | $174.90M | $171.68M | $167.34M |
| Goodwill and Intangible Assets | $175.15M | $125.23M | $174.90M | $171.68M | $167.34M |
| Long Term Investments | $8.95M | $47.16M | $40.48M | $53.17M | $6.31M |
| Tax Assets | $927.07M | $97.21M | $79.22M | $32.19M | $15.04M |
| Other Non-Current Assets | $1.05B | $126.45M | $49.23M | $34.42M | $22.14M |
| Total Non-Current Assets | $1.27B | $418.72M | $360.06M | $307.30M | $222.41M |
| Other Assets | $- | $- | $- | $- | $- |
| Total Assets | $5.99B | $4.54B | $3.13B | $2.85B | $2.28B |
| Account Payables | $627.44M | $245.56M | $188.72M | $208.85M | $206.32M |
| Short Term Debt | $6.31M | $4.65M | $3.42M | $3.51M | $3.48M |
| Tax Payables | $13.39M | $4.33M | $3.18M | $4.32M | $3.50M |
| Deferred Revenue | $- | $- | $- | $- | $46.33M |
| Other Current Liabilities | $-464.63K | $168.46M | $106.96M | $84.56M | $68.87M |
| Total Current Liabilities | $646.67M | $422.99M | $302.28M | $301.24M | $328.49M |
| Long Term Debt | $31.39M | $15.35M | $9.01M | $7.96M | $6.18M |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $269.04M |
| Deferred Tax Liabilities Non-Current | $- | $5.16M | $8.41M | $6.44M | $1.49M |
| Other Non-Current Liabilities | $1.74M | $1.45M | $870.00K | $417.00K | $156.00K |
| Total Non-Current Liabilities | $33.13M | $21.96M | $18.29M | $14.81M | $276.86M |
| Other Liabilities | $- | $- | $- | $- | $- |
| Total Liabilities | $679.80M | $444.95M | $320.56M | $316.05M | $605.36M |
| Preferred Stock | $- | $- | $- | $- | $- |
| Common Stock | $6.98M | $6.39M | $6.20M | $5.48M | $5.74M |
| Retained Earnings | $-1.52B | $-2.40B | $-2.11B | $-1.40B | $-991.93M |
| Accumulated Other Comprehensive Income Loss | $66.71M | $72.07M | $71.72M | $92.39M | $321.21M |
| Other Total Stockholders Equity | $6.75B | $6.42B | $4.85B | $3.84B | $2.34B |
| Total Stockholders Equity | $5.31B | $4.10B | $2.81B | $2.53B | $1.67B |
| Total Equity | $5.31B | $4.10B | $2.81B | $2.53B | $1.67B |
| Total Liabilities and Stockholders Equity | $5.99B | $4.54B | $3.13B | $2.85B | $2.28B |
| Minority Interest | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $5.99B | $4.54B | $3.13B | $2.85B | $2.28B |
| Total Investments | $1.82B | $1.18B | $1.43B | $1.06B | $785.96M |
| Total Debt | $37.70M | $20.00M | $12.43M | $11.46M | $9.66M |
| Net Debt | $-1.41B | $-2.03B | $-788.31M | $-1.32B | $-1.21B |
Balance Sheet Charts
| Breakdown | December 31, 2024 | June 30, 2024 | December 31, 2023 | June 30, 2023 | December 31, 2022 | June 30, 2022 | December 31, 2021 | June 30, 2021 | December 31, 2020 | June 30, 2020 | December 31, 2019 | June 30, 2019 | December 31, 2018 | June 30, 2018 | December 31, 2017 | June 30, 2017 | December 31, 2016 | June 30, 2016 | December 31, 2015 | June 30, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $1.45B | $1.44B | $2.05B | $1.11B | $800.74M | $1.37B | $1.33B | $1.58B | $1.22B | $1.35B | $372.16M | $190.78M | $321.48M | $162.87M | $228.98M | $86.41M | $94.54M | $113.37M | $38.83M | $29.39M |
| Short Term Investments | $1.81B | $1.66B | $1.13B | $886.40M | $1.39B | $1.23B | $1.00B | $1.15B | $779.65M | $822.53M | $1.13B | $882.87M | $324.33M | $228.91M | $202.64M | $111.99M | $7.18M | $7.59M | $7.45M | $27.30M |
| Cash and Short Term Investments | $3.26B | $3.10B | $3.18B | $2.00B | $2.19B | $2.60B | $2.34B | $2.73B | $2.00B | $2.17B | $1.50B | $1.07B | $645.81M | $391.78M | $431.62M | $198.39M | $101.73M | $120.96M | $46.28M | $56.69M |
| Net Receivables | $873.09M | $655.56M | $499.27M | $354.61M | $277.27M | $113.93M | $38.22M | $12.05M | $7.44M | $10.05M | $31.88M | $6.34M | $3.65M | $12.14M | $3.60M | $5.07M | $2.24M | $2.06M | $1.48M | $2.30M |
| Inventory | $393.10M | $326.46M | $310.55M | $201.11M | $228.35M | $135.71M | $109.08M | $59.22M | $25.20M | $5.60M | $- | $2 | $2 | $2 | $2 | $1 | $2 | $2 | $1 | $1 |
| Other Current Assets | $185.89M | $179.42M | $134.07M | $138.82M | $76.02M | $82.31M | $58.95M | $62.40M | $27.91M | $12.22M | $10.14M | $11.39M | $5.36M | $7.41M | $4.83M | $4.64M | $3.08M | $3.17M | $496.36K | $491.26K |
| Total Current Assets | $4.71B | $4.26B | $4.12B | $2.69B | $2.77B | $2.93B | $2.54B | $2.86B | $2.06B | $2.20B | $1.54B | $1.09B | $654.82M | $411.33M | $440.06M | $208.09M | $107.06M | $126.18M | $48.26M | $59.49M |
| Property Plant Equipment Net | $42.01M | $36.93M | $22.68M | $14.68M | $16.23M | $14.24M | $15.84M | $11.39M | $11.58M | $9.90M | $9.18M | $6.69M | $942.58K | $869.46K | $811.00K | $1.01M | $805.60K | $813.12K | $272.23K | $319.66K |
| Goodwill | $6.30M | $9.43M | $- | $15.84M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Intangible Assets | $181.44M | $132.35M | $125.23M | $174.02M | $174.90M | $171.29M | $171.68M | $- | $167.34M | $46.05M | $45.12M | $40.33M | $64.06K | $9.25K | $15.60K | $13.73K | $17.88K | $26.70K | $7.65K | $11.22K |
| Goodwill and Intangible Assets | $175.15M | $141.77M | $125.23M | $189.86M | $174.90M | $171.29M | $171.68M | $175.17M | $167.34M | $46.05M | $45.12M | $40.33M | $64.06K | $9.25K | $15.60K | $13.73K | $17.88K | $26.70K | $7.65K | $11.22K |
| Long Term Investments | $8.95M | $38.61M | $47.16M | $49.91M | $40.48M | $41.42M | $53.17M | $118.02M | $6.31M | $3.87M | $2.92M | $1.70M | $1.14K | $1.16K | $1.20K | $1.14K | $1.05K | $1.11K | $1.09K | $1.12K |
| Tax Assets | $927.07M | $174.63M | $97.21M | $138.77M | $79.22M | $54.27M | $32.19M | $16.25M | $15.04M | $2 | $- | $1 | $1 | $0 | $0 | $0 | $1 | $1 | $-0 | $0 |
| Other Non-Current Assets | $1.05B | $140.83M | $126.45M | $109.06M | $49.23M | $38.72M | $34.42M | $27.52M | $22.14M | $13.14M | $10.33M | $7.28M | $5.87M | $4.04M | $4.10M | $3.07M | $3.36M | $3.49M | $1.71M | $1.33M |
| Total Non-Current Assets | $1.27B | $532.77M | $418.72M | $502.28M | $360.06M | $319.95M | $307.30M | $348.36M | $222.41M | $72.96M | $67.54M | $56.01M | $6.88M | $4.92M | $4.92M | $4.09M | $4.18M | $4.33M | $2.00M | $1.67M |
| Other Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $1 | $- | $- | $- | $1 | $1 | $- | $1 | $1 | $1 | $- |
| Total Assets | $5.99B | $4.80B | $4.54B | $3.19B | $3.13B | $3.25B | $2.85B | $3.21B | $2.28B | $2.27B | $1.61B | $1.15B | $661.70M | $416.26M | $444.98M | $212.19M | $111.24M | $130.51M | $50.25M | $61.15M |
| Account Payables | $627.44M | $280.63M | $245.56M | $195.27M | $188.72M | $167.24M | $208.85M | $239.44M | $206.32M | $143.79M | $65.64M | $62.61M | $27.63M | $24.93M | $5.27M | $14.95M | $4.61M | $5.73M | $4.97M | $5.43M |
| Short Term Debt | $6.31M | $5.85M | $4.65M | $3.20M | $3.42M | $3.49M | $3.51M | $3.45M | $3.48M | $2.54M | $2.22M | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Tax Payables | $13.39M | $13.95M | $4.33M | $4.61M | $3.18M | $3.42M | $4.32M | $1.15M | $3.50M | $484.73K | $386.00K | $1.66M | $941.43K | $653.25K | $716.22K | $682.93K | $- | $- | $- | $- |
| Deferred Revenue | $- | $- | $- | $- | $- | $- | $- | $- | $46.33M | $75.68M | $81.27M | $52.15M | $2.47M | $5.68M | $10.36M | $24.67M | $21.18M | $40.92M | $4.53M | $6.17M |
| Other Current Liabilities | $-464.63K | $199.20M | $168.46M | $114.72M | $106.96M | $90.46M | $84.56M | $- | $68.87M | $3 | $30.19M | $- | $14.78M | $1 | $13.06M | $1 | $8.21M | $1 | $1 | $- |
| Total Current Liabilities | $646.67M | $499.63M | $422.99M | $317.79M | $302.28M | $264.60M | $301.24M | $244.04M | $328.49M | $222.49M | $179.70M | $116.41M | $45.82M | $31.26M | $29.41M | $40.30M | $34.00M | $46.64M | $9.49M | $11.60M |
| Long Term Debt | $31.39M | $28.11M | $15.35M | $8.04M | $9.01M | $6.21M | $7.96M | $4.43M | $6.18M | $5.25M | $5.10M | $4.19M | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $269.04M | $227.81M | $244.94M | $270.23M | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $4.99M | $5.16M | $8.89M | $8.41M | $7.66M | $6.44M | $12.39M | $1.49M | $979.59K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $1.74M | $1.58M | $1.45M | $1.01M | $870.00K | $546.00K | $417.00K | $227.00K | $156.00K | $71.98K | $72.00K | $7.96K | $8.01K | $28.91K | $1.75M | $1.14K | $10.59M | $- | $- | $- |
| Total Non-Current Liabilities | $33.13M | $34.68M | $21.96M | $17.95M | $18.29M | $14.42M | $14.81M | $17.05M | $276.86M | $234.12M | $250.11M | $274.43M | $8.01K | $28.91K | $1.75M | $1.14K | $10.59M | $- | $- | $- |
| Other Liabilities | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $1 | $-0 | $- | $1 | $0 | $- | $- | $- | $- |
| Total Liabilities | $679.80M | $534.31M | $444.95M | $335.74M | $320.56M | $279.02M | $316.05M | $261.09M | $605.36M | $456.61M | $429.81M | $390.84M | $45.83M | $31.29M | $31.16M | $40.30M | $44.59M | $46.64M | $9.49M | $11.60M |
| Preferred Stock | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock | $6.98M | $7.12M | $6.39M | $6.70M | $6.64M | $6.60M | $6.23M | $6.20M | $5.74M | $5.30M | $5.21M | $4.33M | $4.11M | $3.75M | $3.86M | $3.07M | $2.12M | $2.23M | $1.73M | $1.76M |
| Retained Earnings | $-1.52B | $-2.44B | $-2.40B | $-2.23B | $-2.11B | $-1.84B | $-1.40B | $-928.76M | $-991.93M | $-605.30M | $-383.48M | $-244.14M | $-194.01M | $-142.26M | $-120.65M | $-92.30M | $-76.24M | $-65.04M | $-55.89M | $-48.03M |
| Accumulated Other Comprehensive Income Loss | $66.71M | $945.06M | $72.07M | $710.09M | $71.72M | $527.31M | $92.39M | $431.75M | $321.21M | $119.55M | $53.04M | $54.74M | $35.40M | $23.80M | $14.11M | $10.73M | $7.88M | $6.43M | $5.08M | $3.92M |
| Other Total Stockholders Equity | $6.75B | $5.75B | $6.42B | $4.37B | $4.85B | $4.27B | $3.84B | $3.44B | $2.34B | $2.30B | $1.51B | $941.62M | $770.37M | $499.67M | $516.49M | $250.38M | $132.89M | $140.25M | $89.84M | $91.90M |
| Total Stockholders Equity | $5.31B | $4.26B | $4.10B | $2.86B | $2.81B | $2.97B | $2.53B | $2.95B | $1.67B | $1.82B | $1.18B | $756.55M | $615.87M | $384.97M | $413.81M | $171.88M | $66.65M | $83.87M | $40.76M | $49.56M |
| Total Equity | $5.31B | $4.26B | $4.10B | $2.86B | $2.81B | $2.97B | $2.53B | $2.95B | $1.67B | $1.82B | $1.18B | $756.55M | $615.87M | $384.97M | $413.81M | $171.88M | $66.65M | $83.87M | $40.76M | $49.56M |
| Total Liabilities and Stockholders Equity | $5.99B | $4.80B | $4.54B | $3.19B | $3.13B | $3.25B | $2.85B | $3.21B | $2.28B | $2.27B | $1.61B | $1.15B | $661.70M | $416.26M | $444.98M | $212.19M | $111.24M | $130.51M | $50.25M | $61.15M |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $5.99B | $4.80B | $4.54B | $3.19B | $3.13B | $3.25B | $2.85B | $3.21B | $2.28B | $2.27B | $1.61B | $1.15B | $661.70M | $416.26M | $444.98M | $212.19M | $111.24M | $130.51M | $50.25M | $61.15M |
| Total Investments | $1.82B | $1.70B | $1.18B | $936.32M | $1.43B | $1.27B | $1.06B | $1.27B | $785.96M | $826.41M | $1.13B | $884.57M | $324.33M | $228.91M | $202.64M | $111.99M | $7.19M | $7.59M | $7.45M | $27.30M |
| Total Debt | $37.70M | $33.96M | $20.00M | $11.24M | $12.43M | $9.70M | $11.46M | $7.88M | $9.66M | $7.79M | $7.32M | $4.19M | $- | $- | $- | $- | $- | $- | $- | $- |
| Net Debt | $-1.41B | $-1.40B | $-2.03B | $-1.10B | $-788.31M | $-1.36B | $-1.32B | $-1.57B | $-1.21B | $-1.34B | $-364.84M | $-186.59M | $-321.48M | $-162.87M | $-228.98M | $-86.41M | $-94.54M | $-113.37M | $-38.83M | $-29.39M |
Annual Cash Flow
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Net Income | $804.13M | $-425.05M | $-720.34M | $-348.75M | $-477.62M |
| Depreciation and Amortization | $16.92M | $111.31M | $104.34M | $4.96M | $3.92M |
| Deferred Income Tax | $- | $- | $- | $- | $- |
| Stock Based Compensation | $227.02M | $232.97M | $157.03M | $179.37M | $96.93M |
| Change in Working Capital | $-551.68M | $-308.89M | $-375.72M | $-340.95M | $-13.71M |
| Accounts Receivables | $-408.43M | $-185.69M | $-222.26M | $-31.63M | $21.96M |
| Inventory | $-92.66M | $-83.03M | $-119.28M | $-83.88M | $-23.85M |
| Accounts Payables | $- | $- | $- | $- | $- |
| Other Working Capital | $-50.58M | $-40.17M | $-34.19M | $-225.44M | $-11.82M |
| Other Non Cash Items | $-579.14M | $-30.67M | $-28.11M | $-101.44M | $-7.99M |
| Net Cash Provided by Operating Activities | $-82.75M | $-420.33M | $-862.81M | $-606.81M | $-398.46M |
| Investments in Property Plant and Equipment | $-1.74M | $-40.52M | $-837.00K | $-3.62M | $-1.07M |
| Acquisitions Net | $-7.00M | $- | $-2.00M | $- | $- |
| Purchases of Investments | $- | $-1.27B | $-1.69B | $-228.24M | $- |
| Sales Maturities of Investments | $- | $1.54B | $1.26B | $- | $- |
| Other Investing Activities | $-708.86M | $76.47M | $-25.55M | $-115.21M | $345.76M |
| Net Cash Used for Investing Activities | $-717.59M | $308.21M | $-461.18M | $-347.07M | $344.69M |
| Debt Repayment | $-7.37M | $-3.80M | $-4.17M | $-3.85M | $-2.55M |
| Common Stock Issued | $- | $1.20B | $760.95M | $1.09B | $813.19M |
| Common Stock Repurchased | $-21.11M | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- |
| Other Financing Activities | $298.53M | $143.80M | $86.97M | $33.87M | $22.37M |
| Net Cash Used Provided by Financing Activities | $270.05M | $1.34B | $843.76M | $1.12B | $833.00M |
| Effect of Forex Changes on Cash | $-28.33M | $23.49M | $-53.70M | $-49.59M | $65.41M |
| Net Change in Cash | $-407.95M | $1.25B | $-533.94M | $117.87M | $844.64M |
| Cash at End of Period | $1.45B | $2.05B | $800.74M | $1.33B | $1.22B |
| Cash at Beginning of Period | $2.05B | $800.74M | $1.33B | $1.22B | $372.16M |
| Operating Cash Flow | $-79.88M | $-420.33M | $-862.81M | $-606.81M | $-398.46M |
| Capital Expenditure | $-1.74M | $-43.81M | $-103.82M | $-121.43M | $-5.14M |
| Free Cash Flow | $-81.61M | $-464.14M | $-966.63M | $-728.25M | $-403.60M |
Cash Flow Charts
| Breakdown | December 31, 2024 | June 30, 2024 | December 31, 2023 | June 30, 2023 | December 31, 2022 | June 30, 2022 | December 31, 2021 | June 30, 2021 | December 31, 2020 | June 30, 2020 | December 31, 2019 | June 30, 2019 | December 31, 2018 | June 30, 2018 | December 31, 2017 | June 30, 2017 | December 31, 2016 | June 30, 2016 | December 31, 2015 | June 30, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $835.54M | $-30.37M | $-155.63M | $-112.94M | $-255.57M | $-416.10M | $-414.20M | $53.26M | $-312.59M | $-201.64M | $-117.84M | $-45.12M | $-46.56M | $-20.08M | $-19.88M | $-8.20M | $-14.02M | $-7.36M | $-8.29M | $-7.02M |
| Depreciation and Amortization | $8.60M | $7.98M | $98.37M | $4.24M | $94.59M | $2.92M | $2.55M | $2.50M | $1.81M | $1.52M | $1.24M | $927.00K | $273.00K | $220.00K | $220.00K | $215.00K | $184.00K | $150.00K | $108.00K | $88.00K |
| Deferred Income Tax | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Stock Based Compensation | $128.19M | $95.57M | $118.56M | $93.55M | $75.08M | $73.15M | $76.71M | $77.62M | $47.06M | $35.10M | $30.80M | $17.20M | $14.62M | $8.82M | $15.44M | $1.88M | $2.15M | $1.14M | $1.15M | $1.12M |
| Change in Working Capital | $-380.20M | $-165.83M | $-219.42M | $-148.68M | $-229.65M | $-124.23M | $-6.34M | $-129.23M | $-30.54M | $7.95M | $-25.42M | $-8.28M | $7.14M | $-9.71M | $1.59M | $-2.90M | $-426.00K | $-4.46M | $302.00K | $-1.31M |
| Accounts Receivables | $-314.21M | $-91.12M | $-106.56M | $-62.37M | $-141.12M | $-67.91M | $-24.19M | $-3.46M | $2.17M | $17.19M | $-22.79M | $-179.00K | $7.31M | $-7.36M | $2.17M | $-2.29M | $146.00K | $-760.00K | $317.00K | $-968.00K |
| Inventory | $-77.15M | $-15.00M | $-99.88M | $24.96M | $-86.52M | $-25.42M | $-43.81M | $-28.69M | $-15.04M | $-4.88M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Accounts Payables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Working Capital | $11.16M | $-59.71M | $-12.99M | $-111.28M | $-2.01M | $-30.89M | $61.65M | $-97.08M | $-17.68M | $-4.36M | $-2.63M | $-8.10M | $-168.00K | $-2.35M | $-580.00K | $-607.00K | $-572.00K | $-3.70M | $-15.00K | $-347.00K |
| Other Non Cash Items | $-551.67M | $-23.72M | $35.94M | $-97.74M | $-28.40M | $-7.75M | $5.88M | $-193.93M | $90.76M | $23.71M | $17.47M | $263.61M | $-1.73M | $-6.85M | $-18.60M | $-6.32M | $222.00K | $33.01M | $-1.72M | $1.68M |
| Net Cash Provided by Operating Activities | $40.45M | $-116.37M | $-122.18M | $-261.57M | $-343.95M | $-472.01M | $-335.40M | $-189.78M | $-203.51M | $-133.36M | $-93.75M | $228.34M | $-26.25M | $-27.59M | $-21.22M | $-15.32M | $-11.89M | $22.49M | $-8.45M | $-5.45M |
| Investments in Property Plant and Equipment | $-955.65K | $-20.64M | $-301.63K | $-443.28K | $-610.77K | $-174.67K | $-1.08M | $-2.01M | $-268.50K | $-658.53K | $-926.00K | $-678.00K | $-330.00K | $-292.00K | $-19.00K | $-326.00K | $-212.00K | $-628.00K | $-70.00K | $-204.00K |
| Acquisitions Net | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Purchases of Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Sales Maturities of Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Investing Activities | $-195.81M | $-458.95M | $-197.89M | $483.40M | $-213.10M | $-221.60M | $128.70M | $-413.11M | $34.42M | $270.28M | $-220.16M | $-522.58M | $-79.10M | $-27.82M | $-70.65M | $-91.06M | $29.00K | $5.00K | $17.54M | $-454.00K |
| Net Cash Used for Investing Activities | $-196.76M | $-479.59M | $-198.20M | $482.96M | $-213.71M | $-221.77M | $127.62M | $-415.13M | $34.15M | $269.62M | $-221.08M | $-523.26M | $-79.43M | $-28.11M | $-70.67M | $-91.38M | $-183.00K | $-623.00K | $17.47M | $-658.00K |
| Debt Repayment | $- | $-3.36M | $- | $-2.00M | $- | $-2.12M | $- | $-1.52M | $- | $-1.03M | $- | $-536.00K | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock Issued | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock Repurchased | $-19.38M | $-1.67M | $-10.45M | $-553.50K | $-5.47M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $250.75M | $42.45M | $1.16B | $59.63M | $38.60M | $773.62M | $15.83M | $931.85M | $13.45M | $727.71M | $480.03M | $179.87M | $243.00M | $1.68M | $212.17M | $93.19M | $39.00K | $44.58M | $238.00K | $- |
| Net Cash Used Provided by Financing Activities | $231.37M | $37.41M | $1.15B | $57.08M | $33.14M | $771.50M | $15.83M | $930.33M | $13.45M | $726.67M | $480.03M | $179.33M | $243.00M | $1.68M | $212.17M | $93.19M | $39.00K | $44.58M | $238.00K | $- |
| Effect of Forex Changes on Cash | $-15.51M | $-11.44M | $15.88M | $5.46M | $-4.57M | $-46.59M | $-25.25M | $-17.58M | $50.66M | $3.13M | $-1.70M | $2.34M | $2.86M | $4.02M | $-4.94M | $-854.00K | $11.00K | $-42.00K | $51.00K | $130.00K |
| Net Change in Cash | $-1.34B | $1.34B | $-1.02B | $1.02B | $-1.31B | $1.31B | $-1.33B | $1.33B | $-1.20B | $1.20B | $-167.79M | $167.79M | $-140.87M | $140.87M | $-75.53M | $75.53M | $-101.92M | $101.92M | $-26.21M | $26.21M |
| Cash at End of Period | $- | $1.34B | $- | $1.02B | $- | $1.31B | $- | $1.33B | $- | $1.20B | $- | $167.79M | $- | $140.87M | $- | $75.53M | $- | $101.92M | $- | $26.21M |
| Cash at Beginning of Period | $1.34B | $- | $1.02B | $- | $1.31B | $- | $1.33B | $- | $1.20B | $- | $167.79M | $- | $140.87M | $- | $75.53M | $- | $101.92M | $- | $26.21M | $- |
| Operating Cash Flow | $40.45M | $-116.37M | $-122.18M | $-261.57M | $-343.95M | $-472.01M | $-335.40M | $-189.78M | $-203.51M | $-133.36M | $-93.75M | $228.34M | $-26.25M | $-27.59M | $-21.22M | $-15.32M | $-11.89M | $22.49M | $-8.45M | $-5.45M |
| Capital Expenditure | $-955.65K | $-757.07K | $-307.44K | $-443.27K | $-610.77K | $-174.67K | $-1.08M | $-2.01M | $-268.50K | $-658.53K | $-926.00K | $-678.00K | $-330.00K | $-292.00K | $-19.00K | $-326.00K | $-212.00K | $-628.00K | $-70.00K | $-204.00K |
| Free Cash Flow | $39.50M | $-117.12M | $-122.49M | $-262.01M | $-344.56M | $-472.19M | $-336.48M | $-191.79M | $-203.78M | $-134.02M | $-94.68M | $227.66M | $-26.58M | $-27.88M | $-21.24M | $-15.65M | $-12.10M | $21.86M | $-8.52M | $-5.65M |
argenx SE Dividends
Explore argenx SE's dividend history, including dividend yield, payout ratio, and historical payments.
argenx SE News
Read the latest news about argenx SE, including recent articles, headlines, and updates.
argenx Highlights FcRn Leadership with Long-term Data and Transformational Patient Outcomes at the American Academy of Neurology 2025 Annual Meeting
Amsterdam, the Netherlands – March 7, 2025 – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced clinical trial and real-world data for VYVGART® (efgartigimod alfa-fcab) and VYVGART® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) will be presented at the American Academy of Neurology (AAN) Annual Meeting, taking place in San Diego, CA from April 5-9, 2025.
argenx SE (ARGX) Q4 2024 Earnings Call Transcript
argenx SE (NASDAQ:ARGX ) Q4 2024 Earnings Conference Call February 27, 2025 8:30 AM ET Company Participants Beth DelGiacco - Vice President, Corporate Communications and Investor Relations Tim Van Hauwermeiren - Chief Executive Officer Karl Gubitz - Chief Financial Officer Karen Massey - Chief Operating Officer Conference Call Participants Tazeen Ahmad - Bank of America Alex Thompson - Stifel Derek Archila - Wells Fargo Yaron Werber - TD Cowen Victor Floch - BNP Paribas Rajan Sharma - Goldman Sachs Suzanne van Voorthuizen - Kempen Vikram Purohit - Morgan Stanley Matt Phipps - William Blair Gavin Clark-Gartner - Evercore ISI Samantha Semenkow - Citi Thomas Smith - Leerink Partners Leland Gershell - Oppenheimer Mehdi Goudarzi - Truist Securities Douglas Tsao - H. C. Wainwright Manos Mastorakis - Deutsche Bank Operator Good morning.
argenx: Vyvgart's Sales Momentum Improves, Clinical Data Updates From A Key Competitor Imminent
argenx reported Q4 earnings today. Vyvgart's strong Q4 2024 performance, driven by the U.S. CIDP launch, positions it for continued growth with upcoming launches and approvals in Europe, Japan, and the U.S. The sales outlook for 2025 looks strong, and I expect Vyvgart to once again exceed Street expectations. The pipeline catalyst calendar is light for 2025, and several far more important readouts of Vyvgart and one of empasiprubart are expected in 2026.
argenx Reports Full Year 2024 Financial Results and Provides Fourth Quarter Business Update
$737 million in fourth quarter and $2.2 billion in full year global product net sales Received positive CHMP recommendation for VYVGART pre-filled syringe for gMG, enabling launch in the EU; FDA PDUFA (gMG and CIDP) on track for April 10 10 Phase 3 and 10 Phase 2 studies across pipeline ongoing in 2025, positioning for next wave of growth Recognized one-time tax benefit of $725 million related to previously unrecognized deferred tax assets Management to host conference call today at 2:30 PM CET (8:30 AM ET) February 27, 2025 7:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today reported financial results for the full year 2024 and provided a fourth quarter business update. "In 2024, we significantly expanded our global patient reach with VYVGART, surpassing 10,000 patients across three indications,” said Tim Van Hauwermeiren, Chief Executive Officer of argenx.
argenx to Present at TD Cowen 45th Annual Healthcare Conference
February 25, 2025 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that Tim Van Hauwermeiren, Chief Executive Officer, will present at the TD Cowen 45th Annual Healthcare Conference on Monday, March 3, 2025 at 11:50 a.m. ET.
argenx to Report Full Year 2024 Financial Results and Fourth Quarter Business Update on February 27, 2025
February 20, 2025 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, February 27, 2025 at 2:30 PM CET (8:30 AM ET) to discuss its full year 2024 financial results and provide a fourth quarter business update.
argenx to Present at 43rd Annual J.P. Morgan Healthcare Conference
January 6, 2025 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that Tim Van Hauwermeiren, Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 9:45 a.m. PT.
argenx to Present at Upcoming Investor Conferences
November 26, 2024 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that members of the management team will participate in the following upcoming investor conferences in December.
argenx Advances Clinical Development of Efgartigimod SC in Idiopathic Inflammatory Myopathies
Phase 2 data establish proof-of-concept of efgartigimod SC in myositis Enrollment to continue in Phase 3 across all three subtypes (IMNM, ASyS, DM) under evaluation in ALKIVIA Potential for efgartigimod SC to be first targeted approach for myositis patients who have limited treatment options November 20, 2024, 7:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced the decision to continue development of efgartigimod subcutaneous (SC) (efgartigimod alfa and hyaluronidase-qvfc) in the ongoing Phase 2/3 ALKIVIA study in adults with idiopathic inflammatory myopathies (IIM or myositis), following analysis of topline data from the Phase 2 portion of the study. ALKIVIA will continue to enroll patients across each of the three myositis subtypes in the study, including immune-mediated necrotizing myopathy (IMNM), anti-synthetase syndrome (ASyS), and dermatomyositis (DM).
Zai Lab and argenx Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in China
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) and argenx (Euronext & Nasdaq: ARGX) today announced that China's National Medical Products Administration (NMPA) approved the supplemental Biologics License Application (sBLA) for VYVGART Hytrulo 1,000mg (5.6ml)/vial [Efgartigimod Alfa Injection (Subcutaneous Injection)] for the treatment of adult patients with chronic inflammatory demyelinating polyneuropathy (CIDP). VYVGART Hytrulo is approved for CI.
argenx and Zai Lab Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy in China
First and only NMPA-approved treatment for patients with CIDP in China Second VYVGART Hytrulo indication approved in China November 11, 2024 – 7:30am ET Amsterdam, the Netherlands— argenx SE (Euronext & Nasdaq: ARGX) and Zai Lab Limited (Nasdaq: ZLAB; HKEX: 9688) today announced that China's National Medical Products Administration (NMPA) approved the supplemental Biologics License Application (sBLA) for VYVGART Hytrulo 1,000mg (5.6ml)/vial [efgartigimod alfa injection (subcutaneous injection)] for the treatment of adult patients with chronic inflammatory demyelinating polyneuropathy (CIDP). VYVGART Hytrulo is approved for CIDP as a once weekly 30-to-90 second subcutaneous injection.
argenx to Participate at Upcoming Investor Conferences
November 5, 2024 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that members of the management team will participate in the following upcoming investor conferences in November:
Argenx: Strong CIDP Launch, But gMG Growth Propels Q3 Sales Beat
argenx reported strong Q3 results with the sales outperformance being primarily driven by the gMG uptake of Vyvgart. Initial contribution from the CIDP launch also exceeded expectations. The growth outlook for 2025 has further improved after the Q3 results.
argenx SE (ARGX) Q3 2024 Earnings Call Transcript
argenx SE (NASDAQ:ARGX ) Q3 2024 Earnings Conference Call October 31, 2024 8:30 AM ET Company Participants Beth DelGiacco – Vice President, Corporate Communications and Investor Relations Tim Van Hauwermeiren – Chief Executive Officer Karl Gubitz – Chief Financial Officer Karen Massey – Chief Operating Officer Conference Call Participants Derek Archila – Wells Fargo Tazeen Ahmad – Bank of America James Gordon – JPMorgan Allison Bratzel – Piper Sandler Myles Minter – William Blair Alex Thompson – Stifel Danielle Brill – Raymond James Amy Li – Jefferies Yaron Werber – TD Cowen Vikram Purohit – Morgan Stanley Charles Pitman-King – Barclays Samantha Semenkow – Citi Gavin Clark-Gartner – Evercore ISI Suzanne van Voorthuizen – Kempen Joel Beatty – Baird Joon Lee – Truist Securities Victor Floc'h – BNP Paribas Xian Deng – UBS Leland Gershell – Oppenheimer Andy Chen – Wolfe Research Rajan Sharma – Goldman Sachs Thomas Smith – Leerink Partners Douglas Tsao – H. C. Wainwright David Seynnaeve – Petercam Emmanuel Papadakis – Deutsche Bank Simon Baker – Redburn Atlantic Operator Good morning.
argenx Reports Third Quarter 2024 Financial Results and Provides Business Update
$573 million in third quarter global net product sales CIDP global expansion on track, with decisions on approval under review in Japan, Europe, China, and Canada Management to host conference call today at 1:30 PM CET (8:30 AM ET) Regulated information - Inside information October 31, 2024 7:00AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced its third quarter 2024 financial results and provided a business update. “We delivered significant patient impact with VYVGART over the quarter, expanding our gMG footprint and delivering innovation to CIDP patients three months into launch,” said Tim Van Hauwermeiren, Chief Executive Officer of argenx.
argenx to Report Third Quarter 2024 Financial Results and Business Update on October 31, 2024
October 24, 2024 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, October 31, 2024 at 1:30 PM CET (8:30 AM ET) to discuss its third quarter 2024 financial results and provide a business update.
argenx Highlights Data Showing Patient Impact Across Multiple Immunology Programs at 2024 American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting and Myasthenia Gravis Foundation of America Scientific Sessions
Long-term and real-world data of VYVGART® (efgartigimod alfa-fcab) and VYVGART® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) demonstrate speed of onset, depth of response, and durability of response
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for ARGX.